Sign In
Buy VERU
$2.25
-0.100 (-4.26%)
At Close: Jun 03, 2026
Veru Announces Proposed Public Offering
04:01pm, Wednesday, 29'th Oct 2025
MIAMI, FL, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a
MIAMI, FL, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic
Veru Announces Novel Modified-Release Oral Formulation for Enobosarm
10:21am, Friday, 15'th Aug 2025
VERU unveils a novel modified-release oral enobosarm to enhance fat loss while preserving lean mass in chronic weight loss management.
Veru Inc. (VERU) Q3 2025 Earnings Call Transcript
12:57pm, Tuesday, 12'th Aug 2025
Veru Inc. (NASDAQ:VERU ) Q3 2025 Earnings Call August 12, 2025 8:00 AM ET Company Participants K. Gary Barnette - Chief Scientific Officer Michael J.
Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress
06:30am, Tuesday, 12'th Aug 2025
--Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal side
MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and i
Veru Announces Reverse Stock Split
08:30am, Wednesday, 06'th Aug 2025
MIAMI, FL, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a
Veru to Participate in the 2025 BTIG Virtual Biotech Conference
08:30am, Tuesday, 22'nd Jul 2025
MIAMI, FL, July 22, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a
Veru to Participate in the Virtual BTIG Obesity Health Forum
08:30am, Wednesday, 11'th Jun 2025
MIAMI, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a
--Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY trial
Veru: Saving Muscle Mass Amidst The GLP-1 Drug Boom
09:36pm, Monday, 26'th May 2025
Veru Inc. has pivoted to focus on preventing lean mass reduction in patients using GLP-1 agonists, leveraging its lead asset, enobosarm. A Phase 2b trial showed that a 3mg dose of Enobosarm reduces le
Veru Inc. (VERU) Q2 2025 Earnings Call Transcript
12:42pm, Thursday, 08'th May 2025
Veru Inc. (NASDAQ:VERU ) Q2 2025 Results Conference Call May 8, 2025 8:00 AM ET Company Participants Sam Fisch - Executive Director, Investor Relations and Corporate Communications Mitchell Steiner -
Moderated discussion with preeminent obesity expert Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D.
Veru Participates in a Virtual Investor KOL Connect Segment
09:25am, Thursday, 08'th May 2025
-- Moderated discussion with preeminent obesity expert, Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D., F.A.C.S, President, CEO, and Founder, of Veru -- MIAMI, FL, May 08, 2025 (GLOBE NEWSWIRE)
Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress
06:30am, Thursday, 08'th May 2025
--Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the secon
